Equities Analysts Issue Forecasts for MAZE Q2 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Analysts at Wedbush issued their Q2 2025 earnings per share estimates for Maze Therapeutics in a research note issued to investors on Tuesday, July 8th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.77) for the quarter. Wedbush has a "Outperform" rating and a $17.00 price objective on the stock. Wedbush also issued estimates for Maze Therapeutics' Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.39) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.84) EPS.

Separately, Guggenheim reiterated a "buy" rating and issued a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $23.50.

Maze Therapeutics Stock Performance

Maze Therapeutics stock traded down $0.59 during midday trading on Thursday, reaching $15.05. The company's stock had a trading volume of 127,024 shares, compared to its average volume of 119,970. The stock's 50-day simple moving average is $11.65. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $17.00.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. New York State Common Retirement Fund acquired a new position in shares of Maze Therapeutics in the first quarter valued at about $25,000. Corebridge Financial Inc. acquired a new position in shares of Maze Therapeutics in the first quarter valued at about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Maze Therapeutics in the first quarter valued at about $57,000. Rhumbline Advisers acquired a new position in shares of Maze Therapeutics in the first quarter valued at about $80,000. Finally, Deutsche Bank AG acquired a new position in shares of Maze Therapeutics in the first quarter valued at about $98,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.